Moderna details Phase III intismeran data and cancer immunotherapy progress in investor call

Moderna, Inc. (MRNA) convened a conference call on October 24, 2026, to discuss Phase III data for intismeran and advances in cancer immunotherapy, according to a transcript published by Seeking Alpha. The call featured lead investigator Georgina Long presenting results from the INTerpath-001 trial, with commentary from melanoma experts Paolo Ascierto and Antoni Ribas.

What Moderna presented on intismeran

David Berman, Moderna's Chief Development Officer, opened the call by describing the day as "a very exciting day for cancer patients" and "an exciting day for cancer immunologists." He provided context on immune surveillance, explaining how neoantigens form in cancer cells, are carried to regional lymph nodes, processed by antigen-presenting cells, and presented to T cells that then circulate to eliminate cancer. Berman noted that cancer can escape this surveillance when neoantigens are insufficient, not released or transported, or not properly processed and presented.

Georgina Long, the lead investigator for INTerpath-001, reprised her presentation from earlier in the day. Paolo Ascierto, senior author of INTerpath-001, and Antoni Ribas, a melanoma expert and world leader in cancer immunotherapy, also participated. The call included a forward-looking statement and concluding remarks from Berman.

Moderna's pipeline and financial context

According to akta.pro company records, Moderna's collaboration with Merck on intismeran autogene (mRNA-4157/V940), an individualized neoantigen therapy for multiple cancers, produced five-year Phase 2b data showing a 49% reduction in melanoma recurrence or death when combined with Keytruda. The company reported $389 million in Q1 2026 revenue, up 260% year over year, compared with $108 million a year earlier. Moderna's market capitalization stood at approximately $32 billion as of July 2026, and it recorded a $2.8 billion net loss in 2025.

How Moderna reached this point

In October 2026, MarketWatch noted that Moderna was set to release full Phase 3 trial results for its experimental mRNA cancer vaccine that weekend, with the company betting on its custom mRNA technology to treat melanoma and other cancers. Earlier that month, Moderna's president Stephen Hoge said AI accelerates vaccine and drug development but cannot replace biology's timeline, citing a Phase 2 trial with Merck's Keytruda showing about 50% additional benefit over immunotherapy alone, with Phase 3 results pending, as reported by StartupHub.ai. On October 22, 2026, Investors reported that Moderna led the S&P 500 lower on leaked cancer vaccine data.

Next Steps for Moderna

Moderna's Phase III intismeran data and the ongoing INTerpath-001 trial remain the key focus for investors tracking the company's oncology pipeline. The company's partnership with Merck on intismeran autogene continues to advance across multiple cancer types.